Edmond DE Rothschild Holding S.A. Raises Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Edmond DE Rothschild Holding S.A. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 82.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 267,482 shares of the company's stock after purchasing an additional 120,732 shares during the quarter. Edmond DE Rothschild Holding S.A. owned 0.06% of Zoetis worth $43,581,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ZTS. Norges Bank purchased a new stake in shares of Zoetis in the fourth quarter worth about $824,321,000. Wellington Management Group LLP grew its position in shares of Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Zoetis in the fourth quarter worth $196,651,000. Polen Capital Management LLC raised its position in shares of Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after buying an additional 1,116,541 shares in the last quarter. Finally, Amundi raised its position in shares of Zoetis by 46.2% in the fourth quarter. Amundi now owns 2,748,719 shares of the company's stock worth $453,355,000 after buying an additional 867,993 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $215.90.

Remove Ads

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last quarter. Corporate insiders own 0.16% of the company's stock.

Zoetis Trading Down 2.4 %

NYSE ZTS traded down $3.98 on Thursday, hitting $159.52. The company's stock had a trading volume of 2,496,866 shares, compared to its average volume of 2,599,759. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The firm has a market cap of $71.43 billion, a P/E ratio of 29.19, a PEG ratio of 2.78 and a beta of 0.94. The company's 50-day simple moving average is $166.20 and its 200 day simple moving average is $173.98.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. Zoetis's dividend payout ratio (DPR) is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.